4 results
8-K
EX-99.1
BXRX
Baudax Bio, Inc.
6 Oct 23
Departure of Directors or Certain Officers
8:00am
in development & commercial milestones
NMB Portfolio
NMB – Anesthesia Pipeline Continue at modest, sustainable pace Pre-clinical Phase 1 Phase 2 Phase 3
DEFA14A
BXRX
Baudax Bio, Inc.
17 Jul 23
Additional proxy soliciting materials
7:05am
Therapies Companies
NMB Portfolio
NMB – Anesthesia Pipeline Continue at modest, sustainable pace Pre-clinical Phase 1 Phase 2 Phase 3 Milestones … from any depth. Predictable dosing for rapid reversal DURATION OF ACTION TARGET PROFILE
Baudax NMB Portfolio Added value at very modest, sustainable
8-K
EX-99.1
BXRX
Baudax Bio, Inc.
17 Jul 23
Other Events
7:00am
NMB – Anesthesia Pipeline Continue at modest, sustainable pace Pre-clinical Phase 1 Phase 2 Phase 3 Milestones NEUROMUSCULAR BLOCKING AGENTS (NMBs … dosing for rapid reversal DURATION OF ACTION TARGET PROFILE
Baudax NMB Portfolio Added value at very modest, sustainable pace BX1000 BX2000 BX3000
8-K
EX-99.2
BXRX
Baudax Bio, Inc.
9 Nov 20
Baudax Bio Reports Third Quarter 2020 Financial Results
7:10am
by COVID-19 disruption of formulary meetings and elective surgery rates Baudax moves to an even more focused and sustainable footprint around early … traction accounts/areas where we can see deepening usage; believe this is based on modeling successes we have and is a more sustainable model through
- Prev
- 1
- Next